Stocks · News reference
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Neutral and announces $6 price target.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-08 AccNo: 0001193125-26-417935 Size: 186 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Grabar Law Office is investigating securities fraud and fiduciary duty breach claims against four companies: Aardvark Therapeutics for allegedly misrepresenting the safety profile of its drug candidate ARD-101 before a clinical hold was placed; Coastal Financial Corporation for failing to disclose deterioration in its CCBX partner loan portfolio and credit losses; Erasca, Inc. for making misleading statements about its ERAS-0015 therapy and improper comparisons to competitors; and New Era Energy & Digital for overstating progress on its data center project and allegedly engaging in fraudulent oil-and-gas schemes.
Aardvark Therapeutics appointed David Zhang, Ph.D., MBA, as an independent board director, bringing over 25 years of clinical development and regulatory expertise from companies including MyoKardia, Genentech/Roche, Alumis, and Abivax. Zhang will support Aardvark's regulatory strategy for ARD-101, its lead candidate for Prader-Willi Syndrome treatment, at a critical juncture following an FDA clinical hold.
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.